Genetic and environmental effects on the immune phenotypes in type 1 diabetes

Xiaojing Chu[1,2,3,+], Anna W.M. Janssen[4,+], Hans Koenen[5,+], Linzhung Chang[1], Xuehui He[5], Irma Joosten[5], Rinke Stienstra[4,6] Yunus Kuijpers[2,3], Cisca Wijmenga[1], Cheng-Jian Xu[2,3,4], Mihai Netea[4,7], Cees J. Tack[*4], Yang Li[*1,2,3,4]

Affiliations:

[1.] Department of Genetics, University of Groningen, University Medical Center Groningen

[2.] Centre for Individualised Infection Medicine, CiiM, a joint venture between the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany

[3.] TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany

[4.] Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.

[5.] Department of Laboratory Medicine, Laboratory Medical Immunology, Radboud University Medical Center, Nijmegen, the Netherlands.

[6.] Division of Human Nutrition and Health, Wageningen University, the Netherlands.

[7.] Department for Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.

[+] **Shared first authors**
*** Corresponding authors**
Yang Li
Yang.Li@helmholtz-hzi.de
Cees J. Tack
Cees.Tack@radboudumc.nl

Abstract:

Large inter-individual variability in immunological cell composition and function determines immune responses in general and susceptibility of immune-mediated diseases in particular. While much has been learned about the genetic variants relevant for type 1 diabetes, the pathophysiological mechanisms through which these variations exert their effects are unknown. In this study, we characterize the genetic and non-genetic factors influencing immune responses in patients with type 1 diabetes. We show that age and season affect both immune cell traits and cytokine production upon stimulation. Genetic variants that determine susceptibility to T1D significantly affect T cell composition. Specifically, the CCR5+ regulatory T cells associate with T1D through the CCR region, suggesting a shared genetic regulation. Genome-wide quantitative trait loci (QTL) mapping analysis of immune traits revealed 15 genetic loci that influence immune responses in T1D. Among them, 12 have never been reported in healthy population studies, implying a disease-specific genetic regulation.

Key words: functional genomics, type 1 diabetes, immune function

Introduction

46 T1D is a common, chronic, autoimmune disease characterized by auto-immune destruction of
47 insulin-producing beta-cell from the pancreas, that results in lifelong dependence on exogenous
48 insulin and is associated with a high morbidity and mortality *(Atkinson et al., 2014)*. The causes
49 and immunological pathways responsible for the development of T1D are still incompletely
50 understood, which hampers the efforts to identify an etiopathogenetic treatment.

51 Many studies have highlighted the role of environmental, genetical, and immunological factors
52 in the pathogenesis of T1D*(Pociot and Lernmark, 2016; Rewers and Ludvigsson, 2016)*.
53 Environmental factors such as overweight, infections, microbiome composition and dietary
54 deficiencies have been reported as risk factors for T1D*(Rewers and Ludvigsson, 2016)*. In turn,
55 the immunological pathogenesis*(Cabrera et al., 2016)* of T1D includes innate inflammation and
56 adaptive immunity, such as enhanced T cell responses*(Hundhausen et al., 2016)*. Large genome-
57 wide association studies (GWAS) performed in the last two decades have underscored the
58 contribution of genetic polymorphisms for the susceptibility to T1D: ~60 genomic loci
59 associated with T1D risk have been identified (Barrett et al., 2009; Bradfield et al., 2011; Cooper
60 et al., 2008; Grant et al., 2009; Huang et al., 2012; Onengut-Gumuscu et al., 2015; Ram et al.,
61 2016). While these loci show significant enrichment in specific immune-related biological
62 pathways such as cytokine signaling and T cell activation*(Barrett et al., 2009; Cooper et al.,*
63 *2008)*, the functional consequences of many of these loci and genetic variants are still unknown.
64 We thus lack the information that could link the genetic susceptibility factors to the
65 immunological pathways potentially important for T1D pathogenesis. The genetically-regulated
66 inflammatory response signature in T1D may also be relevant for the inflammatory response in
67 general and may become modified by the chronic hyperglycemic state.

68 In the present study we aimed to comprehensively describe the immunopathological
69 consequences of the genetic variants linked to T1D susceptibility, using a high-throughput
70 functional genomics approach. As a part of the Human Functional Genomics Project
71 (HFGP)*(Netea et al., 2016)*, we carried out deep immunophenotyping in peripheral blood
72 samples from a cohort of 243 T1D patients (300DM), covering cell subpopulation composition
73 and cytokine production upon stimulations, as proxies of immunological function. Part of the
74 results were compared to those obtained in a population-based cohort of 500 healthy individuals
75 (500FG), that successfully characterized the impact of both genetic*(Aguirre-Gamboa et al.,*
76 *2016; Li et al., 2016)* and environmental factors*(Aguirre-Gamboa et al., 2016; ter Horst et al.,*
77 *2016)* on immune responses in healthy individuals. Here, we systematically evaluate the impact
78 of host and environmental factors on the immune phenotypes in T1D, and show how age, gender,
79 seasons and genetic variation regulate immune cell traits and cytokine production in response to
80 stimulations. In total, we identified 15 genome wide significant genomic loci (P value $< 5 \times 10^{-8}$)
81 associated with immune phenotypes in the 300DM cohort. Among them, 12 loci have never been
82 reported in any healthy population study. These data provide a deeper understanding of the
83 immune mechanisms involved in the pathophysiology of T1D and affecting the general
84 inflammatory response and may open an avenue towards the development of novel diagnostics
85 and potentially immunotherapies.

86

87 **Results**

88 *Interrelationship between immune cell counts and cytokine production in T1D.*
89 We collected blood samples from 243 T1D patients (300DM cohort), following the same
90 methodology as previously described (Aguirre-Gamboa et al., 2016; ter Horst et al., 2016; Li et

91 al., 2016). The baseline characteristics of the 300DM and a cohort of healthy individuals
92 (500FG) are shown in Supplementary file 1. Their median age was 53.5 years (range 20-85), and
93 they had a median diabetes duration of 28 years (range 1-71 yrs). Hence, the cohort generally
94 consisted of middle-aged people with long standing type 1 diabetes. We measured 72 types of
95 immune cells covering both lymphocytes and monocyte lineages and 10/6 (300DM/500FG)
96 different cytokines released in response to stimulation with four types of human pathogens in
97 both cohorts (Figure 1A).
98 The nonmetric multidimensional scaling plot illustrates the interrelationship among immune
99 cells' abundance (Figure 1B), and cytokine production levels (Figure 1C) in T1D patients. We
100 observed a separation of the B cell subpopulations cluster from the T cell, monocyte, and NK
101 cell population clusters. This observation suggests that T cells, monocytes, and NK cells have
102 more interplay than B cells at baseline, which is consistent with our previous finding in a healthy
103 cohort (500FG(Aguirre-Gamboa et al., 2016)). Furthermore, cytokine features are clustered
104 based on their cellular origins, with a partially overlapping cluster between monocyte-derived
105 cytokines and T cell-derived cytokines Figure 1C). This may suggest activation of a co-
106 regulatory network of monocyte-derived and T cell-derived cytokine production capacity in
107 T1D.
108 To obtain a comprehensive interaction map between immune cells and cytokines, we correlated
109 each of the immune cell counts with each of the cytokine production profiles (IL-1β, IL-6, TNF-
110 α, IL-10, IL-1RA, IL-8, MCP-1, IFNγ, IL-17, and IL-22) in response to 21 stimulations.
111 Cytokine levels were hierarchically clustered based on correlation coefficients with immune cell
112 counts (Figure 1D). In line with the functional relationship between immune cells and cytokines,
113 we observed positive correlations between monocyte lineages and monocyte-derived cytokines

114 (IL-1β, IL-6, TNF-α, IL-10, IL-1RA, IL-8, and MCP-1), as well as between T cell subsets and T
115 cell-derived cytokines (IFNy, IL-17, and IL-22) (indicated by red color in Figure 1D). Besides,
116 we found a negative correlation between monocyte-derived cytokines production in response to
117 four distinct types of stimulations (bacteria, fungi, non-microbial and TLR ligands) and
118 lymphocyte counts (blue, Figure 1D). We observed the similar correlation patterns in 500FG
119 (Figure supplement 1). This correlation matches the findings that a high abundance at baseline of
120 adaptive immune cells is associated with a lower production of monocytes derived cytokines
121 after stimulation*(Dong Kim et al., 2007)*, which is not altered by T1D status. Overall, the inter-
122 relationships between immune cells and cytokines in response to stimulations are rather similar
123 in T1D as compared to healthy individuals.

124 *Age, gender and seasonal effects on immune phenotypes in T1D*

125 To better understand the cause of inter-individual variability in immune traits in T1D patients,
126 we first investigated the effect of age, gender, and season on immune cell proportions. As shown
127 in Figure 2A (and Figure supplement 2A), age is significantly correlated with parental
128 percentage and/or grandparental percentage in 32 (parental) and 36 (grandparental) immune cell
129 measurements (FDR < 0.05) in the 300DM cohort. The strongest correlation is found for naïve
130 CD8 T cells (Figure 2B), that decrease significantly with age, mirrored by an increase in memory
131 cells. These findings confirm the previously found trend in the 500FG cohort (Figure supplement
132 2B), and are in line with other studies involving individuals of European ancestry(Carr et al.,
133 2016; Di Benedetto et al., 2015). This suggests, similar to healthy individuals, that in T1D a
134 transition from naïve cells to more highly differentiated T cell pools occurs along with aging.

135 In addition to age, also season shows an impact on immune cell proportions in T1D. For
136 instance, we observed in the 300DM cohort that the proportion of resting Tregs peak in the

137 summer but maintain a lower level in the winter, while the proportion of effector and memory
138 Tregs are lower in summer but higher in the winter (Figure 2C). This seasonal effect seems
139 stronger in T1D than in healthy individuals (500FG, Figure supplement 2C).

140 We also observed effects of age, gender, and season on cytokines production in response to ex
141 vivo pathogen stimulations in T1D patients (Figure 2D). As an example shown in Figure 2E (and
142 Figure supplement 2D), IFNγ production in response to *C.albicans* hyphae decreases along with
143 aging in 300DM, again similar to the findings in the 500FG cohort, implying a decline of
144 adaptive immunity in older people. Consistent with what we observed on immune cell
145 abundance, age effects seem independent of T1D status. An example of a seasonal effect in
146 cytokine production upon stimulation is that we found a higher production of the pro-
147 inflammatory cytokine IL-6 but a lower production of the anti-inflammatory cytokine IL-10 in
148 winter, both for T1D and healthy individuals (Figure 2F and Figure supplement 2E). Our results
149 replicates known and reveal novel seasonal dynamics of immune system (Dopico et al., 2015).

150

151 *Impact of T1D GWAS SNPs on immune phenotypes in T1D patients*

152 Considering that T1D is a multifactorial disease with a genetic component, we tested whether the
153 known risk variants of T1D affect immune phenotypes and function. We firstly checked SNPs
154 within HLA locus in our association studies on cell proportion and cytokine production level.
155 Consistent with our previous findings in 500FG, we did not observe any significant associations
156 of HLA allelic variants in 300DM.

157 Non-HLA genetic loci from published GWAS studies of European background were acquired
158 from the GWAS-catalog (Nov 2019)*(Buniello et al., 2019)*. Among them, genetic variants in 63

159 independent T1D loci were present in our data, and we found that 13 out of these 63, indeed
160 associated with susceptibility to T1D with nominal significance (P value < 0.05) (Supplementary
161 file 2).

162 Next, we investigated whether these genetic risk loci for T1D affect immune parameters and
163 function. The quantile-quantile (Q-Q) plot of the association of the 63 T1D GWAS loci with
164 different cell types and cytokines illustrates an inflated deviation from an expected uniform
165 distribution (Figure 3A, Figure supplement 3). We further tested whether this deviation can be
166 explained by chance by comparing the association of immune traits with T1D GWAS SNPs with
167 that of 1000 randomly selected independent SNPs (Figure 3B, Methods). The p value shows that
168 the T1D GWAS SNPs are enriched in association with T-cell traits in the T1D cohort (P value =
169 0.007).

170 A pair-wise association analysis between T1D GWAS loci and immune phenotypes shows that
171 261 out of 269 immune cell phenotypes and 53 out of 55 cytokine-stimulation pairs are
172 suggestively associated with at least one T1D GWAS locus (P value < 0.05, Supplementary file
173 3, 4). We further applied a permutation-based approach to test whether immune phenotypes were
174 significantly influenced by the accumulative effects of these 63 GWAS loci (Methods).
175 Compared to random sets of independent SNPs, the 63 T1D GWAS loci explain significantly
176 more variance of 27 cell sub proportions and 15 cytokine production traits (P value < 0.05,
177 Figure 3C, Figure supplement 4A, B). As shown in the heatmap (Figure 3C, arrowhead), a T1D
178 risk allele rs11574435-T, in strong LD (r^2 = 0.95) with the T1D GWAS SNP
179 rs113010081*(Onengut-Gumuscu et al., 2015)*, is associated with higher percentage of many
180 CCR5+ CD4+ T-cell traits and lower percentage of CCR5- CD4+ T-cell traits. Chemokine
181 signaling pathways regulate the migration of cells from the circulation (PBMCs) to the tissue

182 (pancreases). To further validate the importance of chemokine signaling mediated by *CCR5* in
183 T1D, we illustrated the transcriptional changes on *CCR5* and its corresponding ligand genes
184 using publicly available data from transcriptome analysis in PBMCs and pancreatic tissue from
185 T1D patients and controls *(Planas et al., 2010; Yang et al., 2015)*(See also Methods), and found
186 significant expression changes of *CCR5*, *CCL5*, and *CCL4* in T1D patients, suggesting the
187 involvement of this chemokine ligand - chemokine receptor pathway (Figure 3D). Besides,
188 another top SNP-rs35092096 within the *CCR* genes region has the strongest effects on many
189 CCR5 Tregs proportions in T1D. For example, the minor allele T in rs35092096 associates with
190 a higher ratio of CCR6+CCR7-CCR5+ Tregs/ CCR6+ T regs (Figure 3E, F). Together with the
191 observed regulation from a GWAS locus within the *CCR* region on CCR6+CCR7-CCR5+ Tregs
192 proportion, we tested whether CCR6+CCR7-CCR5+ Tregs and T1D shared the same causal
193 variants/genomic regions by integrating the cell proportion QTL of CCR6+CCR7-CCR5+ Tregs
194 and the latest T1D GWAS profile using colocalization analysis*(Giambartolomei et al., 2014)*.
195 The result strongly supports that CCR6+CCR7-CCR5+ Tregs share the same regulatory genomic
196 region with T1D, although the causal SNP might be different (Figure 3G, H3 = 0.95).
197 Altogether, these results support a role of the *CCR* region on Tregs function in the pathogenesis
198 of T1D.

199 Overall, we observed that T1D GWAS loci influence immune cell proportion and cytokine
200 production capacity, again stressing the importance of T cell immunity in the genetic regulation
201 of T1D.

202

203 *Genetic regulation of immune phenotypes in T1D*

204 To further explore potential genetic regulation of immune phenotypes on the whole-genome
205 level, we performed quantitative trait loci (QTL) mapping in 300DM. We identified nine
206 genome-wide significant QTLs (P value < $5x10^{-8}$) associated with immune cell proportion,
207 including four associated with T cell subpopulations expressing specific chemokine receptors
208 (e.g., rs35092096 and rs7614884) (Figure 4A, top and middle panels, Supplementary file 5). A
209 pathway analysis of the cell proportion QTLs shows significant enrichment in chemokine and
210 cytokine signaling-related biological pathways (FDR < 0.05, Figure supplement 5A),
211 highlighting the effects of immune signaling genes in cell proportion regulation.
212
213 In parallel, we detected six significant genomic loci associated with cytokine production in
214 response to stimulations by QTL mapping in 300DM (Figure 4A, bottom panel, Supplementary
215 file 5). TLR-related pathways significantly enrich cytokine production QTLs (FDR < 0.05,
216 Figure supplement 5B). A missense variant, rs5743618, on the *TLR1* gene, affects IL-6
217 production in response to *S.pneumoniae* in PBMC. Previously, we observed the strong effect of
218 the TLR locus on cytokine levels in controls*(Li et al., 2016)*. Our results support the reported
219 function of TLRs in detecting pathogens (including bacterial) and triggering the release of
220 inflammatory cytokines*(Fitzgerald and Kagan, 2020)*.
221
222 Next, to identify the consistent immune phenotype QTLs within T1D patients and healthy
223 individuals, and to expand our understanding on genetic regulation of immune phenotypes, we
224 applied a meta-analysis by integrating the obtained QTLs from the 300DM and 500FG cohorts.
225 In total, we newly identified ten genetic loci that were associated with immune cell proportion
226 (Figure 4A, top panel, colored in red) and three genetic loci that were associated with cytokine

227 production (Figure 4A, bottom panel, colored in red), including a *CD5* locus significantly
228 associated with IgD+ CD5++ proportion in B cells (Supplementary file 5). This may be
229 important as recent studies report the relevance of IgD+ CD5++ B cells in T1D*(Saxena et al.,*
230 *2017)* as well as within other autoimmune diseases such as Graves' disease*(van der Weerd et al.,*
231 *2013)*.
232
233 To summarize, we identified 28 genetic loci associated with either immune cell traits or cytokine
234 production phenotypes. Among them, the genes within 11 loci (+- 250kb window) are druggable
235 according to public drug database*(Finan et al., 2017)*, including *COL13A1*, *CCR* family genes,
236 *ROR2*, *NOS1*, *IL-10*, *IL-6*, *STK33*, *NELL1, FCGR2A, CD5* and *TLR1* (Supplementary file 5).
237 Some of these genes are already therapeutic targets in other autoimmune diseases, such as the
238 *STK33* inhibitor for rheumatoid arthritis treatment*(Rolf et al., 2015)*.
239 It is also worth mentioning that, as far as we know, 12 out of the 28 significant loci have never
240 been reported in other healthy individual population cohorts according to records in
241 PhenoScanner V2 (Kamat et al., 2019) (P value $< 1 \times 10^{-5}$, November, 2019), neither were they
242 identified in the 500FG cohort (P value < 0.05). An example of a T1D specific locus is that
243 rs4744112 located on chromosome 9 has an influence on CCR6+CXCR3+CCR4- Th1 like
244 helper proportion (Figure 4B), with minor allele G leading to a decrease in these cells relative to
245 major allele T (Figure 4C). rs4744112 is located within the transcriptional starting site (TSS) and
246 enhancer regions*(Roadmap Epigenomics Consortium et al., 2015)* of *ROR2*.
247
248 *Functional Clues from the Associated Variants in T1D patients*

249 In order to understand the mechanism behind the genetic regulations of immune response in
250 T1D, we next explored the function of identified genetic factors of immune phenotypes. We
251 noticed that SNPs within the 28 immune parameter QTLs are mostly located in the intergenic
252 and intronic region (Figure supplement 6), suggesting that identified genetic variants influence
253 immune phenotypes through regulatory effects rather than through protein structure alteration.
254 Moreover, seven out of 28 loci influence blood gene expression in public databases*(Carithers*
255 *and Moore, 2015; Westra et al., 2013)* (Supplementary file 5) including rs7512140:
256 FCGR2B/FCRLB, rs35092096: CCR1/CCR3, rs4744112: ROR2/SPTLC1, rs10840031:
257 TRIM66, rs800139: C11orf21, rs1518110: IL10 and rs56350303: AC091814.2. These indicate
258 the potential functional genes behind the identified genetic loci.
259
260

261 **Discussion**

262 The present study applies a high-throughput functional genomics approach to identify the
263 association between various genetic and non-genetic host factors and the inflammatory phenotype
264 in patients with T1D. The results demonstrate a correlation between baseline immune cell
265 populations and ex vivo cytokine production in response to bacteria, fungi, non-microbial and TLR
266 ligand stimulations, and reveal the influence of age and seasons on immune phenotype variability.
267 Regarding genetic factors, we provide evidence for a direct link between T1D GWAS loci and
268 immune functionality, particularly on circulating T cell subpopulations. We show that T cell
269 alteration is largely driven by T1D genetics, while B cells do not show a significant association
270 with T1D GWAS loci. The association between the proportion of CCR5+ Tregs and T1D
271 susceptibility through CCR genes suggests that T1D associated genetic variants contribute to

272 immune function alteration through an accumulative effect. Finally, out of 28 genome-wide
273 significant genetic loci regulating immune cell proportions and cytokine production, we identified
274 12 immune phenotype QTLs specific to 300DM. We also found 11 druggable genes as candidates
275 for therapeutic intervention. Altogether, this study provides several novel insights into the
276 environmental and genetic variability of immune traits in T1D.

277 Our finding of a correlation between baseline immune cells and cytokine production in response
278 to bacteria, fungi, non-microbial and TLR ligand stimulations, suggests that steady-state immune
279 cell abundance and alteration of immune cell proportion also affects immune response. This is in
280 line with earlier findings on the regulation between immune cells and cytokine production*(Dong*
281 *Kim et al., 2007)*. This finding has two important consequences: the immune response variability
282 could be partly explained by variation in steady-state, and treatment of steady-state immune cells
283 before stimulation could also influence immune response after stimulation. The influence of age
284 and seasons on immune phenotypes variability has been reported before*(Aguirre-Gamboa et al.,*
285 *2016; Di Benedetto et al., 2015)*. In our cohorts, we observed that the age effect is independent of
286 T1D status. We observed stronger immune function in winter than in summer. This observation
287 might be relevant in the context of the finding that the incidence of new-onset T1D diagnosis is
288 higher in winter than summer*(Moltchanova et al., 2009)*. The fact that steady-state immune cell
289 proportions of T1D patients are more affected by seasons compared to that of healthy individuals,
290 suggests that environmental effects are more visible in the context of autoimmune diseases.

291 Recent studies show that immune-related genes are physically located in T1D loci or differentially
292 expressed when comparing T1D patients and healthy controls. More studies highlight the
293 importance of T cell immunity in T1D pathology*(Farh et al., 2015)*. In our study, we provide
294 evidence for a direct link between T1D GWAS loci to immune functionality, particularly on

295 circulating T cell subpopulations. We show that T cell alteration is largely driven by T1D genetics
296 and, interestingly, B cells do not show a significant association with T1D GWAS loci. It is thus
297 tempting to speculate whether the occurrence of auto-antibodies in T1D patients has
298 pathophysiological relevance, or whether they are merely markers of an autoimmune process
299 mainly driven by T-cells(Martin et al., 2001).
300
301 Importantly, we reveal that the effects of different GWAS loci on immune phenotypes vary.
302 Despite the strong effects of the CCR locus (mean absolute effect sizes = 0.017 (cell proportion),
303 0.15 (cytokine production)), we observed much weaker individual effects from other T1D GWAS
304 loci on immune cell proportion parameters (mean absolute effect size = 0.0060) and/or cytokine
305 production (mean absolute effect size = 0.10) (Figure 3C and Figure supplement 4). This finding
306 indicates that T1D-associated genetic variants might alter immune function through a cumulative
307 effect. Considering the complexity of the immune system, it may be an alternative explanation for
308 our finding that T1D associated genetic variants affect immune functions through pathways
309 different from affecting immune cell proportion and cytokine production capacity.
310
311 Despite the limited sample size, we identified 28 genome-wide significant genetic loci regulating
312 immune cell proportions and cytokine production in T1D patients and health. Among them, 12
313 immune phenotype QTLs are specifically found in 300DM, but not in healthy volunteers,
314 suggesting a distinct regulatory mechanism of immune parameters and functions between disease
315 and health. More importantly, in our study, we highlight 11 druggable genes as candidates for
316 therapeutic intervention.

317 The data presented in our study are generated from PBMC. While these likely reflect overall
318 immune function, some immune cell types may not be captured and all over the findings refer to
319 changes in circulating factors that may not necessarily reflect changes occurring in relevant
320 immune organs, such as gut or lymph nodes.
321 We acknowledged that our study has limitations. Firstly, 300DM and 500FG are two independent
322 cohorts, so there may be some differences in the absolute immune cell counts or cytokine levels
323 due to a batch effect. Therefore, this study was not designed as a case-control study, but the healthy
324 controls were used to compare associations identified in the T1D cohort. While young people were
325 overrepresented in 500FG, we identified similar age and seasonal effects in both cohorts, also after
326 adjustment for baseline differences. Thirdly, not all the immune traits were measured in both
327 300DM and 500FG cohorts. Finally, our type 1 diabetes-specific analyses should be viewed
328 exploratory as they have not been validated in a separate cohort. Our study has also strengths: it
329 applied cutting-edge technologies to assess immune cell function and genetic variation, and it is
330 the first study which comprehensively combines 'omics' technologies to abundant phenotyping in
331 a rather large group of participants to explain between individuals' variation in immune responses.
332 In conclusion, we applied a novel high-throughput functional genomics approach, and show a
333 link between genetic, host and environmental factors that regulate the immune responses in T1D
334 patients. We show genetic susceptibility to immune phenotypes in patients with T1D, and
335 highlight the importance of T cell immunity in the genetic regulation of T1D. We identify
336 specific cell populations that are likely involved in pathophysiology of T1D (CCR5+ T-regs).
337 Together, these findings may provide an avenue towards identification of novel preventive and
338 therapeutic treatments.

339

340 **Materials and Methods**

341 **Study cohort.** This study mainly focuses on a 300DM cohort, and involves a 500FG cohort (part
342 of HFGP*(Netea et al., 2016)*). In total, 132 males and 111 females of Caucasian origin with T1D
343 were recruited in the 300DM cohort at the Radboudumc, the Netherlands. Their age ranges from
344 20 to 84 years. Detailed information of 500FG cohort can be found in the previous
345 publications(Aguirre-Gamboa et al., 2016; ter Horst et al., 2016; Li et al., 2016).

346

347 **Measurement of Immune Cell composition.** Myeloid and lymphoid immune cell levels were
348 measured by 10-color flow cytometry. The parental and grandparental proportion from 73
349 manually annotated immune cells as well as the proportion of CD4+ T cells, CD8+ T cells,
350 memory T regulatory cells and monocytes carrying chemokine receptors: CCR6 (CD196),
351 CXCR3 (CD183), CCR4 (CD194), CCR5 (CD195) and CCR7 (CD197) were calculated
352 respectively, and end up with 277 immune cell traits of the 300DM cohort. We used the same
353 gating strategy of measuring cell subpopulations as 500FG (See reference*(Aguirre-Gamboa et*
354 *al., 2016)* and Figure supplement 7).

355

356 **Stimulation of PBMCs and measurement of Cytokine production capacity.** Isolation of
357 PBMCs were washed twice with cold phosphate-buffered saline (PBS) and suspended in Roswell
358 Park Memorial Institute (RPMI) 1640 Dutch-modified culture medium (Gibco/Invitrogen, Breda,
359 the Netherlands) supplemented with 50 mg/l gentamycin (Centraform), 1 mM pyruvate
360 (Gibco/Invitrogen) and 2mM L-glutamine (Gibco/Invitrogen). Cells were counted on a Sysmex
361 XN-450 Hematology Analyzer (Sysmex Corporation, Kobe, Japan).

362 For *in vitro* stimulation experiments, $5x10^5$ cells/well were cultured for 24hr or 7 days at 37°C and
363 5% CO_2 in 96-well round-bottom plates (Greiner). For the 7 days cultures, medium was
364 supplemented with human pooled serum (pooled from healthy blood donors, end concentration
365 10%). Supernatants were collected and stored in -20°C until used for ELISA.
366 The following stimulations were used: (LPS (100ng/ml, 1ng/ml), Pam3cys, *Borrelia* mix, *C.*
367 *albicans* conidia, *C. albicans* hyphae, Imiquimod (IMQ), *S. aureus*, *S. pneumoniae*, palmitic acid
368 (C16), C16+ monosodium urate crystals (MSU), *E. coli*, *M. tuberculosis* (MTB), *B. burgdorferi*,
369 *C. burnetii*, *C. neoformans*, Oxidized low-density lipoprotein (OxLDL), OxLDL+ LPS,
370 Polyinosinic:polycytidylic acid (Poly IC), *Rhizopus* microspores, *Rhizopusoryzae*)*(Li et al.,*
371 *2016)*. Concentrations of monocyte-derived cytokines (IL-1β, IL-6, TNF-α, IL-8, IL-10, IL-1Ra,
372 MCP-1) and T cell-derived cytokines (INF-γ, IL-17, IL-22) in response to various stimulations
373 were measured in peripheral blood mononuclear cells (PBMC) by ELISA kits following the
374 manufacturers protocol. For all cytokines commercially available kits were used (R&D Systems,
375 MN, USA or Sanquin, Amsterdam, the Netherlands).
376
377 **Genotyping, quality control and imputation.** DNA samples of 224 Dutch T1D patients were
378 collected and genotyped by the Infinium® Global Screening Array. The genotype calling was
379 performed using Opticall 0.7.0*(Shah et al., 2012)* with default settings (call rate > 0.99). One
380 sample was removed due to contamination; one sample from related individual (identity be
381 descent > 0.185) was removed and seven genetic outliers were identified by either heterozygosity
382 rate check or multi-dimensional scaling plots of samples merging with 1000 Genomes data,
383 leaving 215 samples according to standard protocol (Anderson et al., 2010). DNA samples from
384 the 500FG cohort were genotyped by Illumina Human OmniExpress Exome-8 v1.0 SNP chip.

385 Outliers were excluded according to population relationship, medication and disease information.
386 Details can be found in our previous studies in 500FG*(Aguirre-Gamboa et al., 2016; Li et al.,*
387 *2016)*. Single-nucleotide polymorphisms (SNPs) with a minor allele frequency (MAF) < 0.001
388 were removed from each cohort, and a Hardy-Weinburg equilibrium (HWE) P value < 1×10^{-5}
389 were removed for the healthy cohort (500FG). By taking shared genetic variants, we merged the
390 300DM cohort and 500FG cohort, and we used an online genotype imputation service provided
391 by Michigan Imputation Server (https://imputationserver.sph.umich.edu)*(Das et al., 2016)* with
392 HRC Panel 1.1 as reference. SNPs with low imputation quality (R2 < 0.3) and/or MAF < 0.01 in
393 all imputed samples and/or HWE p values < 1×10^{-5} in healthy individuals were excluded leaving
394 4304387 SNPs and 666 individuals (N_{300DM} = 215 and N_{500FG} = 451).
395
396 **Statistical Analysis**
397 All statistical analyses were performed using the statistical programming language R. Immune
398 cell proportion was calculated by dividing counts of their parental and grandparental cell types
399 (Supplementary file 6). An inverse rank transformation(Aguirre-Gamboa et al., 2016; Orrù et al.,
400 2013) was applied on the proportion values for genetic association analysis. Cytokine levels were
401 log2 transformed. Associations with age, gender, seasonal effect were then calculated using
402 previously described methods(Aguirre-Gamboa et al., 2016; ter Horst et al., 2016; Li et al.,
403 2016), i.e. Spearman correlation analysis and linear regression model. Significance was declared
404 after multiple testing correction (FDR < 0.05).
405
406 **Immune parameter QTL mapping.** After intersecting with available genotype data and
407 excluding volunteers with a mixture or another genetic background, 214 were left for immune

408 parameter quantitative trait locus (QTL) mapping. We next evaluated covariates influencing
409 immune function. We took age, gender and seasonal effects as covariables in the linear
410 regression for both immune cell proportion QTL mapping as well as cytokine QTL mapping.
411 Besides, considering the effect of immune cell proportion on cytokine production, we took major
412 cell types, including monocyte, lymphocyte, T cell, B cell and NK cell proportion in PBMC as
413 covariables in a linear model for cytokine QTL mapping, as we previously did*(Li et al., 2016)*.
414 Linear regression function was applied with an R package Matrix-eQTL*(Shabalin, 2012)* for
415 immune parameter QTL mapping, and software METAL*(Willer et al., 2010)* was used for meta-
416 analysis. P values $< 5\times10^{-8}$ were considered to be genome-wide significant. Lambda values were
417 calculated indicating no obvious inflations (0.977-1.026).
418
419 **Extraction of T1D GWAS SNP list.** We downloaded a summary of T1D GWAS results from
420 GWAS-catalog (https://www.ebi.ac.uk/gwas/)*(Buniello et al., 2019)* in November 2019, and
421 removed studies done in non-European-ancestry populations. Top SNPs within LD ($r^2 > 0.1$)
422 from different studies were considered as the same locus, and SNPs with the lowest p value were
423 taken into analysis. We noticed that the effect directions of some SNPs were unclear or
424 inconsistent in different studies. In this case, we assigned directions according to the newest
425 GWAS study*(Onengut-Gumuscu et al., 2015)*.
426
427 **GWAS analysis of 300DM cohort for the known T1D loci.** We extracted all proxies in strong
428 LD with top SNPs from published T1D GWAS (Case-Control) studies ($r^2 > 0.8$) and performed a
429 chi-square test on clinical status by using PLINK 1.9. Samples in 300DM were taken as cases
430 and samples in 500FG were controls.

431

432 **Impact of T1D GWAS loci on immune phenotypes.** In order to detect the impact of T1D
433 GWAS loci on immune cell populations, we grouped all traits into four categories (B cells, T
434 cells, monocytes and NK cells), and counted the number of suggestive associations (P value <
435 0.05) between 63 top SNPs from T1D GWAS loci and immune cell traits. We then compared it
436 with associations between 1000 permuted sets of 63 independent SNPs and the same category of
437 immune traits. P value was calculated by the percent of association numbers from permuted sets
438 greater than the association number of the 63 T1D GWAS SNPs.
439 We further applied a multivariate linear model to estimate the proportion of variance of each
440 immune phenotype explained by the top SNPs from T1D GWAS loci. We repeated this analysis
441 on 1000 permuted sets of 63 independent SNPs, which were used as reference set. We then
442 compared the null distribution with variance explained by 63 top SNPs from T1D GWAS loci. P
443 value was calculated by the percent of explained variance from permuted sets larger than the
444 variance explained by the 63 T1D GWAS SNPs.
445

446 **Gene expression analysis on *CCR5* and its corresponding ligands genes**. Normalized gene
447 expression data in PBMCs and Pancreases from T1D and controls were acquired from
448 https://www.ebi.ac.uk/gxa*(Papatheodorou et al., 2019)*. A *Student's* t-test was applied to
449 compare gene expression between groups.
450

451 **Post-QTL analysis.** An R package ggplot2 was used to generate Manhattan plots and boxplots.
452 Locus-zoom plots were made by an online tool(http://locuszoom.org)*(Pruim et al., 2010)*. We
453 used an R package coloc*(Giambartolomei et al., 2014)* to perform colocalization analysis with

454 T1D GWAS summary statistics and immune parameter QTLs profile. For pathway analysis**,**

455 genes located within +-10kb of genome wide significant SNPs (p value < 5×10^{-8}) were extracted

456 and analyzed by an online tool FUMA*(Watanabe et al., 2017)* (https://fuma.ctglab.nl).

457 ANNOVAR was used for annotating genetic variants*(Wang et al., 2010)*.

458

459 **Other packages used in this paper.** Pheatmap was used to make heatmaps. Scatter plots and

460 bar plots were generated by ggplot2.

461

462 **References and Notes:**

463 Aguirre-Gamboa, R., Joosten, I., Urbano, P.C.M., van der Molen, R.G., van Rijssen, E., van
464 Cranenbroek, B., Oosting, M., Smeekens, S., Jaeger, M., Zorro, M., et al. (2016). Differential
465 Effects of Environmental and Genetic Factors on T and B Cell Immune Traits. Cell Reports *17*,
466 2474–2487.

467 Anderson, C.A., Pettersson, F.H., Clarke, G.M., Cardon, L.R., Morris, A.P., and Zondervan,
468 K.T. (2010). Data quality control in genetic case-control association studies. Nat Protoc *5*, 1564–
469 1573.

470 Atkinson, M.A., Eisenbarth, G.S., and Michels, A.W. (2014). Type 1 diabetes. The Lancet *383*,
471 69–82.

472 Barrett, J.C., Clayton, D.G., Concannon, P., Akolkar, B., Cooper, J.D., Erlich, H.A., Julier, C.,
473 Morahan, G., Nerup, J., Nierras, C., et al. (2009). Genome-wide association study and meta-
474 analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. *41*, 703–707.

475 Bradfield, J.P., Qu, H.-Q., Wang, K., Zhang, H., Sleiman, P.M., Kim, C.E., Mentch, F.D., Qiu,
476 H., Glessner, J.T., Thomas, K.A., et al. (2011). A genome-wide meta-analysis of six type 1
477 diabetes cohorts identifies multiple associated loci. PLoS Genet. *7*, e1002293.

478 Buniello, A., MacArthur, J.A.L., Cerezo, M., Harris, L.W., Hayhurst, J., Malangone, C.,
479 McMahon, A., Morales, J., Mountjoy, E., Sollis, E., et al. (2019). The NHGRI-EBI GWAS
480 Catalog of published genome-wide association studies, targeted arrays and summary statistics
481 2019. Nucleic Acids Research *47*, D1005–D1012.

482 Cabrera, S.M., Chen, Y.-G., Hagopian, W.A., and Hessner, M.J. (2016). Blood-based signatures
483 in type 1 diabetes. Diabetologia *59*, 414–425.

484 Carithers, L.J., and Moore, H.M. (2015). The Genotype-Tissue Expression (GTEx) Project.
485 Biopreservation and Biobanking *13*, 307–308.

486 Carr, E.J., Dooley, J., Garcia-Perez, J.E., Lagou, V., Lee, J.C., Wouters, C., Meyts, I., Goris, A.,
487 Boeckxstaens, G., Linterman, M.A., et al. (2016). The cellular composition of the human
488 immune system isshaped by age and cohabitation. Nat Immunol *17*, 461–468.

489 Cooper, J.D., Smyth, D.J., Smiles, A.M., Plagnol, V., Walker, N.M., Allen, J.E., Downes, K.,
490 Barrett, J.C., Healy, B.C., Mychaleckyj, J.C., et al. (2008). Meta-analysis of genome-wide
491 association study data identifies additional type 1 diabetes risk loci. Nat. Genet. *40*, 1399–1401.

492 Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A.E., Kwong, A., Vrieze, S.I., Chew, E.Y.,
493 Levy, S., McGue, M., et al. (2016). Next-generation genotype imputation service and methods.
494 Nat Genet *48*, 1284–1287.

495 Di Benedetto, S., Derhovanessian, E., Steinhagen-Thiessen, E., Goldeck, D., Müller, L., and
496 Pawelec, G. (2015). Impact of age, sex and CMV-infection on peripheral T cell phenotypes:
497 results from the Berlin BASE-II Study. Biogerontology *16*, 631–643.

498 Dong Kim, K., Zhao, J., Auh, S., Yang, X., Du, P., Tang, H., and Fu, Y.-X. (2007). Adaptive
499 immune cells temper initial innate responses. Nat Med *13*, 1248–1252.

500 Dopico, X.C., Evangelou, M., Ferreira, R.C., Guo, H., Pekalski, M.L., Smyth, D.J., Cooper, N.,
501 Burren, O.S., Fulford, A.J., Hennig, B.J., et al. (2015). Widespread seasonal gene expression
502 reveals annual differences in human immunity and physiology. Nat Commun *6*, 7000.

503 Farh, K.K.-H., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W.J., Beik, S., Shoresh, N.,
504 Whitton, H., Ryan, R.J.H., Shishkin, A.A., et al. (2015). Genetic and epigenetic fine mapping of
505 causal autoimmune disease variants. Nature *518*, 337–343.

506 Finan, C., Gaulton, A., Kruger, F.A., Lumbers, R.T., Shah, T., Engmann, J., Galver, L., Kelley,
507 R., Karlsson, A., Santos, R., et al. (2017). The druggable genome and support for target
508 identification and validation in drug development. Sci. Transl. Med. *9*, eaag1166.

509 Fitzgerald, K.A., and Kagan, J.C. (2020). Toll-like Receptors and the Control of Immunity. Cell
510 *180*, 1044–1066.

511 Giambartolomei, C., Vukcevic, D., Schadt, E.E., Franke, L., Hingorani, A.D., Wallace, C., and
512 Plagnol, V. (2014). Bayesian Test for Colocalisation between Pairs of Genetic Association
513 Studies Using Summary Statistics. PLoS Genet *10*, e1004383.

514 Grant, S.F.A., Qu, H.-Q., Bradfield, J.P., Marchand, L., Kim, C.E., Glessner, J.T., Grabs, R.,
515 Taback, S.P., Frackelton, E.C., Eckert, A.W., et al. (2009). Follow-up analysis of genome-wide
516 association data identifies novel loci for type 1 diabetes. Diabetes *58*, 290–295.

517 ter Horst, R., Jaeger, M., Smeekens, S.P., Oosting, M., Swertz, M.A., Li, Y., Kumar, V.,
518 Diavatopoulos, D.A., Jansen, A.F.M., Lemmers, H., et al. (2016). Host and Environmental
519 Factors Influencing Individual Human Cytokine Responses. Cell *167*, 1111-1124.e13.

520 Huang, J., Ellinghaus, D., Franke, A., Howie, B., and Li, Y. (2012). 1000 Genomes-based
521 imputation identifies novel and refined associations for the Wellcome Trust Case Control
522 Consortium phase 1 Data. Eur. J. Hum. Genet. *20*, 801–805.

523 Hundhausen, C., Roth, A., Whalen, E., Chen, J., Schneider, A., Long, S.A., Wei, S., Rawlings,
524 R., Kinsman, M., Evanko, S.P., et al. (2016). Enhanced T cell responses to IL-6 in type 1
525 diabetes are associated with early clinical disease and increased IL-6 receptor expression. Sci.
526 Transl. Med. *8*, 356ra119-356ra119.

527 Kamat, M.A., Blackshaw, J.A., Young, R., Surendran, P., Burgess, S., Danesh, J., Butterworth,
528 A.S., and Staley, J.R. (2019). PhenoScanner V2: an expanded tool for searching human
529 genotype-phenotype associations. Bioinformatics *35*, 4851–4853.

530 Li, Y., Oosting, M., Smeekens, S.P., Jaeger, M., Aguirre-Gamboa, R., Le, K.T.T., Deelen, P.,
531 Ricaño-Ponce, I., Schoffelen, T., Jansen, A.F.M., et al. (2016). A Functional Genomics
532 Approach to Understand Variation in Cytokine Production in Humans. Cell *167*, 1099-1110.e14.

533 Martin, S., Wolf-Eichbaum, D., Duinkerken, G., Scherbaum, W.A., Kolb, H., Noordzij, J.G., and
534 Roep, B.O. (2001). Development of Type 1 Diabetes despite Severe Hereditary B-Cell
535 Deficiency. N Engl J Med *345*, 1036–1040.

536 Moltchanova, E.V., Schreier, N., Lammi, N., and Karvonen, M. (2009). Seasonal variation of
537 diagnosis of Type 1 diabetes mellitus in children worldwide. Diabetic Medicine *26*, 673–678.

538 Netea, M.G., Joosten, L.A.B., Li, Y., Kumar, V., Oosting, M., Smeekens, S., Jaeger, M., ter
539 Horst, R., Schirmer, M., Vlamakis, H., et al. (2016). Understanding human immune function
540 using the resources from the Human Functional Genomics Project. Nat Med *22*, 831–833.

541 Onengut-Gumuscu, S., Chen, W.-M., Burren, O., Cooper, N.J., Quinlan, A.R., Mychaleckyj,
542 J.C., Farber, E., Bonnie, J.K., Szpak, M., Schofield, E., et al. (2015). Fine mapping of type 1
543 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene
544 enhancers. Nat. Genet. *47*, 381–386.

545 Orrù, V., Steri, M., Sole, G., Sidore, C., Virdis, F., Dei, M., Lai, S., Zoledziewska, M., Busonero,
546 F., Mulas, A., et al. (2013). Genetic Variants Regulating Immune Cell Levels in Health and
547 Disease. Cell *155*, 242–256.

548 Papatheodorou, I., Moreno, P., Manning, J., Fuentes, A.M.-P., George, N., Fexova, S., Fonseca,
549 N.A., Füllgrabe, A., Green, M., Huang, N., et al. (2019). Expression Atlas update: from tissues to
550 single cells. Nucleic Acids Research gkz947.

551 Planas, R., Carrillo, J., Sanchez, A., Ruiz de Villa, M.C., NuÃ±ez, F., Verdaguer, J., James,
552 R.F.L., Pujol-Borrell, R., and Vives-Pi, M. (2010). Gene expression profiles for the human
553 pancreas and purified islets in Type 1 diabetes: new findings at clinical onset and in long-
554 standing diabetes. Clinical & Experimental Immunology *159*, 23–44.

555 Pociot, F., and Lernmark, Å. (2016). Genetic risk factors for type 1 diabetes. The Lancet *387*,
556 2331–2339.

557 Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, T.P., Boehnke, M.,
558 Abecasis, G.R., and Willer, C.J. (2010). LocusZoom: regional visualization of genome-wide
559 association scan results. Bioinformatics *26*, 2336–2337.

560 Ram, R., Mehta, M., Nguyen, Q.T., Larma, I., Boehm, B.O., Pociot, F., Concannon, P., and
561 Morahan, G. (2016). Systematic Evaluation of Genes and Genetic Variants Associated with Type
562 1 Diabetes Susceptibility. J.I. *196*, 3043–3053.

563 Rewers, M., and Ludvigsson, J. (2016). Environmental risk factors for type 1 diabetes. The
564 Lancet *387*, 2340–2348.

565 Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen,
566 A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015). Integrative analysis
567 of 111 reference human epigenomes. Nature *518*, 317–330.

568 Rolf, M.G., Curwen, J.O., Veldman-Jones, M., Eberlein, C., Wang, J., Harmer, A., Hellawell,
569 C.J., and Braddock, M. (2015). In vitro pharmacological profiling of R406 identifies molecular
570 targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect *3*, e00175.

571 Saxena, A., Yagita, H., Donner, T.W., and Hamad, A.R.A. (2017). Expansion of FasL-
572 Expressing CD5+ B Cells in Type 1 Diabetes Patients. Front. Immunol. *8*.

573 Shabalin, A.A. (2012). Matrix eQTL: ultra fast eQTL analysis via large matrix operations.
574 Bioinformatics *28*, 1353–1358.

575 Shah, T.S., Liu, J.Z., Floyd, J.A.B., Morris, J.A., Wirth, N., Barrett, J.C., and Anderson, C.A.
576 (2012). optiCall: a robust genotype-calling algorithm for rare, low-frequency and common
577 variants. Bioinformatics *28*, 1598–1603.

578 Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic
579 variants from high-throughput sequencing data. Nucleic Acids Research *38*, e164–e164.

580 Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). Functional mapping
581 and annotation of genetic associations with FUMA. Nat Commun *8*, 1826.

582 van der Weerd, K., Van Hagen, P.M., Schrijver, B., Kwekkeboom, D.J., de Herder, W.W., ten
583 Broek, M.R.J., Postema, P.T.E., van Dongen, J.J.M., Staal, F.J.T., and Dik, W.A. (2013). The
584 peripheral blood compartment in patient with Graves' disease: activated T lymphocytes and
585 increased transitional and pre-naive mature B lymphocytes: T and B lymphocytes in Graves'
586 disease. Clin Exp Immunol n/a-n/a.

587 Westra, H.-J., Peters, M.J., Esko, T., Yaghootkar, H., Schurmann, C., Kettunen, J., Christiansen,
588 M.W., Fairfax, B.P., Schramm, K., Powell, J.E., et al. (2013). Systematic identification of trans
589 eQTLs as putative drivers of known disease associations. Nat Genet *45*, 1238–1243.

590 Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis of
591 genomewide association scans. Bioinformatics *26*, 2190–2191.

592 Yang, M., Ye, L., Wang, B., Gao, J., Liu, R., Hong, J., Wang, W., Gu, W., and Ning, G. (2015).
593 Decreased miR-146 expression in peripheral blood mononuclear cells is correlated with ongoing
594 islet autoimmunity in type 1 diabetes patients. Journal of Diabetes *7*, 158–165.

595

596 **Acknowledgements:**

597 We thank all of the volunteers in the 300DM and 500FG for their participation. We thank Marc J.

598 Bonder for discussions.

599

600 **Funding:**

601 This work was supported by an ERC starting Grant (no. 948207) and a Radboud University

602 Medical Centre Hypatia Grant (2018) to Y.L. and an ERC advanced grant (no. 833247) and a

603 Spinoza grant of the Netherlands Association for Scientific Research to M.G.N. C.T received

604 funding from the Perspectief Biomarker Development Center Research Programme, which is

605 (partly) financed by the Netherlands Organisation for Scientific Research (NWO). AJ was funded

606 by a grant from the European Foundation for the Study of Diabetes (EFSD/AZ Macrovascular

607 Programme 2015). X.C was supported by China Scholarship Council.

608

609 **Author contributions:**

610 Y.L., C.T. and M.G.N designed the study. X.C. performed statistical analysis supervised by Y.L.,

611 A.J., H.K., X.H. and I.J. performed the experiments and processed the data. L.C. and C.X. helped

612 with the data analysis. Y.L., C.T., M.G.N, C.W and X.C interpreted the data. Y.L., C.T., M.G.N.

613 and X.C wrote the manuscript with input from all authors.

614

615 **Competing interests:**

616 The authors declare that they have no competing interests.

Data and code availability

All raw data of immune phenotypes have been deposited in Dryad (https://doi.org/10.5061/dryad.4f4qrfjd0). Individual genetic data and other privacy-sensitive individual information are available upon request to corresponding authors by email or at Human Functional Genomics Project website (http://hfgp.bbmri.nl). This dataset is not publicly available because it contains information that could compromise research participant privacy, while summary statistics directly generated from genetic data that will precisely reproduce published results are all deposited in Dryad (https://doi.org/10.5061/dryad.4f4qrfjd0). Custom scripts for generating summary statistics and all results are deposited in GitHub (https://github.com/Chuxj/Gf_of_ip_in_T1D)

Ethical statement

The 500FG-DM study was approved by the ethical committee of Radboud University Nijmegen (NL-number: 54214.091.15). Experiments were conducted according to the principles expressed in the Declaration of Helsinki. Written informed consent was obtained from all participants.

Figures:

Fig. 1



Figure 1. Overview of data and experimental design. **A**, Schematic of study design. **B**,**C**, Cell (**B**) and cytokine (**C**) type relationship visualized by non-metric multidimensional scale (NMDS) analysis in 300DM. In panel **B**, Small dots indicate the proportion of subpopulations and large dots indicate counts of their parental cell types. Circles represent the calculated centroid of the grouped cell and cytokine types at confidence level 0.95. **D**, Heatmap of correlation coefficients between immune cell counts (y-axis) and cytokine production in response to stimulations (x-axis) in T1D patients. Significant correlations (FDR <0.05) are labeled by dots, with the color indicating correlation coefficients.

Fig. 2



Figure 2. Impact of age, gender and seasons on immune phenotypes. **A**, Heatmap of correlation between immune cell counts (y-axis) and age, gender, seasons (x-axis). Correlation coefficients were indicated by colors, and significant correlations (FDR <0.05) are labeled by dots. **B**,**C**, Scatter plots showing examples of age (**B**) and seasonal effects (**C**) on cell proportions in 300DM. **D**, Heatmap of correlation between cytokines levels upon stimulations and age, gender, seasons. Correlation coefficients were indicated by colors, and significant correlations (FDR <0.05) are labeled by dots. **E**,**F**, Scatter plots showing examples of age (**E**) and seasonal effects (**F**) on cytokine levels upon stimulations in 300DM.

Fig. 3



Figure 3. Impact of T1D GWAS SNPs on immune phenotypes. **A**, Qqplots of QTL profiles of 62 T1D GWAS loci grouped by cell populations. **B**, Histogram showing number of associations observed (red) and those in permutations. **C**, Heatmap of QTL profiles of cell proportion carrying certain chemokine receptors across 62 T1D GWAS loci, colored by -log10(p values) and effect direction of T1D risk allele. **D**, Expression of *CCR5*, *CCL5* and *CCL4* in PBMC (top) and Pancreases (bottom) altered in T1D patients

662 compared to healthy controls. **E**, A locus zoom plot showing SNPs around rs35092096
663 located in CCR region have effects on CCR6+CCR7-CCR5+ T reg proportion. **F**, A
664 boxplot showing CCR6+CCR7-CCR5+ T reg proportion differs in different rs35092096
665 genotypes. **G**, Two locus zoom plots indicating colocalization between CCR6+CCR7-
666 CCR5+ T reg proportion QTL profiles and T1D GWAS profile within CCR regions.

Fig. 4


A
FCGR2A
RP5-934G17.6
SNORA64
STK31
PDSS2
COG5
PTPRD
COL13A1
LHPP
C11orf21
STK33
IGSF9B
CD5
NOS1
CTD-2544M6.1
cell proportion
CCR3
LSAMP
ROR2
PCBD1
cell proportion with chemokine receptor
TLR1
ST6GALNAC3
IL10
TMEM87B
LOC340017
IL6
SH3GL2
NELL1
CLEC9A
Cytokine production
-log10(p value)
Chromosome
B
Plotted SNPs
rs4744112
Recombination rate (cM/Mb)
Position on chr9 (Mb)
C
Thelper1 CCR6+CXCR3+CCR4-_GrandParentalPercentage
TT
TG
GG
rs4744112

667

668 **Figure 4.** Genetic regulators on immune phenotypes. **A**, Three Manhattan plots showing genetic
669 regulators of immune cell proportion (top), proportion of immune cells expressing CCR
670 (middle) and cytokines production in response to stimulations (bottom). P values of SNPs
671 identified in meta-analysis were colored in red. **B**, A locus zoom plot showing a T1D
672 specific regulatory locus around rs4744112 that effects CCR6+CXCR3+CCR4- T
673 helper1 proportion. **C**, A boxplot showing CCR6+CXCR3+CCR4- T helper1 proportion
674 varies in different rs4744112 genotypes.